Welcure Drugs & Pharmaceuticals has announced a set of measures to boost shareholder participation and support its upcoming growth plans, including a bonus issue, stock split, and plans to raise funds through a qualified institutional placement (QIP).
According to The Economic Times, the company’s board approved a bonus share issue in the ratio of 1:10, granting one additional share for every ten held, alongside a stock split of one equity share of ₹10 each into ten equity shares of ₹1 each. The decisions are aimed at enhancing liquidity and broadening the investor base following the company’s strong financial performance in the first quarter of FY26.
In addition, the board has cleared a proposal to raise up to ₹80 crore via QIP in one or more tranches to finance expansion initiatives. This includes plans for an agro-pharma research laboratory, with an estimated investment of ₹70–80 crore. The proposed QIP will provide the company with the financial flexibility to support its capital expenditure and research-driven growth trajectory.
For stakeholders, the developments signal the company’s intent to strengthen its position in the domestic pharmaceutical market by aligning corporate actions with its long-term R&D and manufacturing expansion priorities. Investors and analysts will be closely watching the execution of the fund-raising plan, particularly as competition intensifies in the generics and agro-pharma segments.
